This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Competition for clients, talent, resources and mindshare is tougher for salons than it's ever been. Boulevard's Jozlyn Miller offers four pillars of modern salon success and how to plan for each.
As New York passes legislation than evens the educational playing field for textured hair, Vagaro's VP of Marketing Charity Hudnall shares her personal story and her opinion on how things might change.
In honor of Mental Health Awareness month, three beauty professionals share their insight, tips and advice for those who are looking to make changes at how they address mental health in the hair and beauty industry.
Scores for erythema, dryness, quality of life, and aesthetic improvement were all markedly improved in patients using tranexamic acid versus traditional therapy alone.
Kids whose parents use e-cigarettes may be at higher risk for developing atopic dermatitis (AD), a new study suggests. Children with a parent who used e-cigarettes had 24% higher odds for AD than kids with two non-vaping parents, according to a survey of more than 35,000 U.S. households. The prevalence of parental e-cigarette use was 14.4% in the non-AD population and 18.0% in the AD population.
Kids whose parents use e-cigarettes may be at higher risk for developing atopic dermatitis (AD), a new study suggests. Children with a parent who used e-cigarettes had 24% higher odds for AD than kids with two non-vaping parents, according to a survey of more than 35,000 U.S. households. The prevalence of parental e-cigarette use was 14.4% in the non-AD population and 18.0% in the AD population.
Tiffani Botts Massey, PA-C, Florida Society of Dermatology PAs President Elect, and Heather Gates, PA-C, the organization's current president, preview the upcoming conference.
TDD Editorial Advisory Board Member Raj Chovatiya, MD, PhD, the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, updates viewers on the true role of Malassezia yeast in the pathophysiology of seborrheic dermatitis and explains how this new understanding is changing the way the condition is treated. The post The New Thinking About Seb Derm With Raj Chovatiya, MD, PhD appeared first on The Dermatology Digest.
Allan chats with guest Kelly Gasspari-Flemming! They covered: How a child starts in the Wellness business 30 years later Smile more From Nails to Blueprints Finding your love language Top Tips on a Podcast and more! Get it on: iTunes Podbean Spotify Continue reading Flock and Gather Podcast. Episode 177 with guest Kelly Gasspari-Flemming from the Waldorf Astoria Chicago at Spa Industry Association.
Eco-Friendly Amenity Sets New Hospitality Standards in Sustainability, Comfort, and Guest Experience GARNER, N.C., May 15, 2024 (Newswire.com) – Feelgoodz, a trailblazer in sustainable footwear, proudly announces the launch of Bodhi, an innovative spa slide from their Zero Waste Back Bar Collection, poised to redefine guest experiences in the spa industry.
Bimekizumab-bkzx (Bimzelx, UCB) consistently showed sustained improvements in clinical and patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa (HS), according to results from the Phase 3 BE HEARD I and BE HEARD II trials. Bimekizumab-bkzx is an interleukin (IL)-17A and IL-17F inhibitor. The findings, which are published in the Lancet , support global regulatory submissions for bimekizumab-bkzx in HS. “The Phase 3 studies with bimekizumab represent a signi
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content